血栓通注射液联合鼠神经生长因子治疗非动脉炎性前部缺血性视神经病变的疗效观察

发布时间：2018-02-17 07:21

本文关键词： 血栓通注射液注射用鼠神经生长因子前部缺血性视神经病变视野缺损 P波潜伏期　出处：《现代药物与临床》2016年01期 　论文类型：期刊论文

【摘要】：目的探讨血栓通注射液联合鼠神经生长因子治疗非动脉炎性前部缺血性视神经病变(AION)的疗效观察。方法选取2013年6月—2015年6月沈阳市第四人民医院眼科收治的非动脉炎性AION患者88例,按治疗方案的差别将患者分为对照组和治疗组,每组各44例。对照组肌肉注射注射用鼠神经生长因子,18μg/次加入到0.9%生理盐水或灭菌注射用水2 m L中溶解,1次/d。治疗组在对照组治疗基础上静脉滴注血栓通注射液,5 m L加入到0.9%生理盐水250 m L,1次/d。两组患者均连续治疗4周。观察两组的临床疗效,同时比较两组视野缺损(MD)、P100波潜伏期、视盘各象限视神经纤维层厚度(ATRNFL)、视力提高行数。结果治疗后,对照组和治疗组的总有效率分别为77.27%、93.18%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者MD、P100潜伏期较治疗前显著减小,同组治疗前后差异具有统计学意义(P0.05);且治疗组的改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组ATRNFL均较治疗前减小,但治疗后治疗组ATRNFL较对照组高,两组比较差异具有统计学意义(P0.05);并且治疗后对照组ATRNFL较正常值低。治疗组的视力提高行数高于对照组,两组比较差异具有统计学意义(P0.05)。结论血栓通注射液联合鼠神经生长因子治疗非动脉炎性AION具有较好的临床疗效,可明显改善视力,有效提高视野,具有一定的临床推广应用价值。
[Abstract]:Objective to investigate the therapeutic effect of Xuetong injection combined with nerve growth factor (NGF) on anterior ischemic optic neuropathy (AION) of non-arteritis. Methods from June 2013 to June 2015, non-AION of 4th people's Hospital of Shenyang was selected. 88 patients with arteritis AION, The patients were divided into control group and treatment group according to the difference of treatment plan. There were 44 cases in each group. The control group was injected with nerve growth factor 18 渭 g / time to 0.9% normal saline or sterilized injection water 2 mL once a day. The treatment group was treated with intravenous drip of thrombus on the basis of the treatment in the control group. The patients in the two groups were treated continuously for 4 weeks. The clinical effects of the two groups were observed. At the same time, the latency of MDN P100 wave, the thickness of optic nerve fiber layer and the number of improved visual acuity in each quadrant of optic disc were compared between the two groups. Results after treatment, the total effective rates of the control group and the treatment group were 77.27 and 93.18, respectively. The difference between the two groups was statistically significant (P 0.05). The latent period of MDP100 in the two groups was significantly lower than that before and after treatment, and the difference between the same group before and after treatment was statistically significant (P 0.05), and the improvement of the treatment group was better than that of the control group, and the difference between the two groups was statistically significant (P 0.05). After treatment, the ATRNFL of the two groups decreased compared with that before treatment. But after treatment, the ATRNFL of the treatment group was higher than that of the control group, and the difference between the two groups was statistically significant (P 0.05), and the ATRNFL value of the control group was lower than that of the control group, and the visual acuity of the treatment group was higher than that of the control group. Conclusion Xueshuantong injection combined with nerve growth factor has a better clinical effect on non-arterial inflammatory AION, which can obviously improve visual acuity and visual field. It has certain value of clinical popularization and application.
【作者单位】：沈阳市第四人民医院眼科;
【分类号】：R774.6

【参考文献】